Lonza's Synaffix platform has entered a licensing collaboration with Qurient Therapeutics to develop a novel dual-payload antibody-drug conjugate (ADC) integrating Synaffix’s exatecan technology with Qurient’s CDK7 inhibitor. This ADC strategy aims to deliver two cytotoxic mechanisms simultaneously, potentially overcoming resistance and increasing efficacy in solid tumor therapies. Qurient will lead R&D and commercialization, with Lonza providing manufacturing and platform support, signaling a strategic advance in targeted cancer therapeutics.